Cargando…
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
The humanised anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (formerly EMD 72000) is active against pancreatic cancer in preclinical studies. This phase I study assessed the safety and potential benefit of combined treatment with matuzumab and standard-dose gemcitabine. T...
Autores principales: | Graeven, U, Kremer, B, Südhoff, Th, Killing, B, Rojo, F, Weber, D, Tillner, J, ünal, C, Schmiegel, W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361405/ https://www.ncbi.nlm.nih.gov/pubmed/16622465 http://dx.doi.org/10.1038/sj.bjc.6603083 |
Ejemplares similares
-
Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development
por: Kuester, K, et al.
Publicado: (2008) -
Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab
por: Meira, Debora D, et al.
Publicado: (2011) -
Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.
por: Bruynck, A., et al.
Publicado: (1993) -
A 72,000-mol-wt protein from tomato inhibits rabbit acto-S-1 ATPase activity
Publicado: (1983) -
In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Blumenthal, R D, et al.
Publicado: (2008)